Biljana Horn

Biljana Horn, M.D.

CLIN PROF

Department: MD-PEDS-HEMATOLOGY
Business Phone: (415) 215-6930

About Biljana Horn

Dr. Horn, director of our Pediatric Bone Marrow Transplant and Cell Therapy Program, earned her medical degree at the University of Zagreb. She completed a pediatric residency at Case Western Reserve University, followed by a fellowship in pediatric hematology/oncology at the National Cancer Institute and another in pediatric neuro-oncology at UCSF. Her research efforts have focused on developing reduced intensity conditioning regimens for children, improving outcomes for children with brain tumors by using high-dose chemotherapy and stem cell support, reducing transplant-related mortality, reducing relapse after transplant and developing regimens for transplant of newborns with immune deficiencies. She is a member of the AAP, the Children’s Oncology Group, the American Society of Hematology, the American Society for Blood and Marrow Transplantation, the Pediatric Blood and Marrow Transplant Consortium and the Foundation for the Accreditation of Cellular Therapy.

Accomplishments

Exceptional Physician Award
2016 · UCSF Medical Center
Thrasher Research Fund Award
2011 · Thrasher Research Fund
Hellman Family Award
2003 · Hellman Foundation
Travel Award for Research in Oncology
1994 · American Association for Cancer Research

Clinical Profile

Specialties
  • Pediatrics
Subspecialties
  • Pediatric Hematology-Oncology
Areas of Interest
  • Bone marrow transplant
  • Graft-versus-host disease
  • Leukemia
  • Leukemia – resources
  • Lymphoma – Overview
  • Non-Hodgkin lymphoma

Research Profile

Areas of Interest
  • Bone marrow transplantation
  • Chimerism
  • Complications of HSCT
  • High dose chemotherapy for brain tumors
  • Prevention of relapse following bone marrow transplantation
  • Reduced intensity conditioning
  • Veno-occlusive liver disease (VOD)

Grants

Jul 2019 ACTIVE
A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID receiving TCRaB+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatr
CHILDRENS HOSP LOS ANGELES · Principal Investigator
Apr 2019 ACTIVE
Pharmacogenomics and Toxicities of Thiotepa, Busulfan and Fludarabine in Pediatric HSCT Recipients
LIVE LIKE BELLA PEDIATRIC CANCER RESEARC ·

Education

Fellowship
1994 · National Cancer Institute
Residency
1991 · Case Western Reserve
M.D.
1987 · University of Zagreb, Croatia

Contact Details

Phones:
Business:
(415) 215-6930